Skip to main content

Advertisement

SpringerLink
Log in

Angiotensin II and the glomerulus: Focus on diabetic kidney disease

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The renin-angiotensin system plays a key role in the progression of kidney disease, in addition to its well-described role in the maintenance of extracellular fluid volume and blood pressure. Recent studies have shown that blockade of the renin-angiotensin system at the level of the angiotensin II type 1 receptor can have important effects on proteinuria and the rate of progression of kidney disease in patients with type 2 diabetes mellitus. This review first discusses recent experimental studies relating angiotensin II to kidney function in diabetes mellitus and changes in glomerular permselectivity, and then focuses on recent clinical trials with angiotensin II receptor blockers in patients with type 2 diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Burns KD, Homma T, Harris RC: The intrarenal reninangiotensin system. Semin Nephrol 1993, 13:13–30.

    PubMed  CAS  Google Scholar 

  2. Burns KD: Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000, 36:449–467. This is one of the most complete reviews of Ang II receptors and diabetic nephropathy. The article is extensively referenced.

    PubMed  CAS  Google Scholar 

  3. Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925–1930.

    PubMed  CAS  Google Scholar 

  4. Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382–2391.

    PubMed  CAS  Google Scholar 

  5. Anderson S, Jung FF, Inglefinger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265:F477-F486.

    PubMed  CAS  Google Scholar 

  6. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.

    Article  Google Scholar 

  7. UKPDS 39: U.K. Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998, 317:713–720.

    Google Scholar 

  8. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all type 1 diabetic patients with microalbuminuria receive ACE inhibitor treatment? A meta regression analysis. Ann Intern Med 2001, 134:370–379.

    Google Scholar 

  9. Cooper ME: Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and II diabetic patients. J Hypertens 1996, 14:S11-S14.

    Article  CAS  Google Scholar 

  10. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939–945.

    Article  PubMed  CAS  Google Scholar 

  11. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857–1863.

    Article  Google Scholar 

  12. Miller JA: Impact of hyperglycemia on the renin-angiotensin system in early human type I diabetes mellitus. J Am Soc Nephrol 1999, 10:1778–1785. This paper reveals an important direct effect of hyperglycemia on activation of the systemic and renal RAS in human diabetic subjects.

    PubMed  CAS  Google Scholar 

  13. Zimplemann J, Kumar D, Levine DZ, et al.: Early diabetes mellitus stimulates tubule renin mRNA expression in the rat. Kidney Int 2000, 58:2320–2330. This paper provides the first measures of renal tissue Ang II levels in an animal model of diabetes mellitus. The diabetes-induced increase in Ang II was glucose dependent.

    Article  Google Scholar 

  14. Correa-Rotter R, Hostetter TH, Rosenberg ME: Renin and angiotensinogen gene expression in experimental diabetes mellitus. Kidney Int 1992, 41:796–804.

    PubMed  CAS  Google Scholar 

  15. Zhang S-L, Filep JG, Hohman TC, et al.: Molecular mechanism of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999, 55:454–464.

    Article  PubMed  CAS  Google Scholar 

  16. Brown L, Wall D, Marchant C, Sernia C: Tissue-specific changes in angiotensin II receptors in streptozotocindiabetic rats. J Endocrinol 1997, 154:355–362.

    Article  PubMed  CAS  Google Scholar 

  17. Kalinyak JE, Sechi LA, Griffin CA, et al.: The renin-angiotensin system in streptozocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 1993, 4:1337–1345.

    PubMed  CAS  Google Scholar 

  18. Wang T-T, Wu X-H, Zhang S-L, Chan JSD: Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int 1998, 53:312–319.

    Article  PubMed  CAS  Google Scholar 

  19. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448–1456.

    Article  PubMed  CAS  Google Scholar 

  20. El Nahas AM: Progression of chronic renal failure. In Comprenhensive Clinical Nephrology. Edited by Johnson RJ, Feehally J. New York: Mosby Harcourt; 2000:6690–6710.

    Google Scholar 

  21. Breyer JA, Bain RP, Evans JK, et al.: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996, 50:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  22. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995, 123:754–762.

    PubMed  CAS  Google Scholar 

  23. Burton C, Harris KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996, 27:765–775.

    PubMed  CAS  Google Scholar 

  24. Abbate M, Zoja C, Corna D, et al.: Progressive nephropathies: overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998, 9:1213–1224.

    PubMed  CAS  Google Scholar 

  25. Ruggenenti P, Perna A, Gherardi G, et al.: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000, 35:1155–1165.

    PubMed  CAS  Google Scholar 

  26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting enzyme on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  27. Microalbuminuria Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria: the Microalbuminuria Captopril Study Group. Diabetologia 1996, 39:587–593.

    Google Scholar 

  28. Viberti G, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994, 271:275–279.

    Article  PubMed  CAS  Google Scholar 

  29. Parving H-H, Lehnert H, Brochner-Mortensen J, et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. This is an important study because the authors report that Ang II blockade limits the progression of diabetic nephropathy from the stage of microalbuminuria to overt nephropathy in patients with type 2 diabetes mellitus.

    Article  PubMed  CAS  Google Scholar 

  30. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002, 106:672–678.

    Article  PubMed  CAS  Google Scholar 

  31. Lacourciere Y, Belanger A, Godin C, et al.: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kindey Int 2000, 58:762–769.

    Article  CAS  Google Scholar 

  32. Brenner BM, Cooper ME, De Zeeuw D, et al., for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. This is an important study because the authors report that Ang II blockade limits the progression of diabetic nephropathy in patients with type 2 diabetes mellitus and overt nephropathy.

    Article  PubMed  CAS  Google Scholar 

  33. Lewis EJ, Hunsicker LG, Clarke WR, et al., for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860. This is also an important study because the authors report that Ang II blockade limits the progression of diabetic nephropathy in patients with type 2 diabetes mellitus and overt nephropathy.

    Article  PubMed  CAS  Google Scholar 

  34. Remuzzi A, Perico N, Sangalli F, et al.: ACE inhibition and Ang II blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999, 276:F457-F466.

    PubMed  CAS  Google Scholar 

  35. Deen WM, Bridges CR, Brenner BM, Myers BD: Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. Am J Physiol 1985, 249:F374-F389.

    PubMed  CAS  Google Scholar 

  36. Blantz RC, Konnen KS, Tucker BJ: Angiotensin effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976, 57:419–434.

    PubMed  CAS  Google Scholar 

  37. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001, 38:635–638.

    PubMed  CAS  Google Scholar 

  38. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993, 3:1531–1540.

    PubMed  CAS  Google Scholar 

  39. G, Ziyadeh FN, Zahner G, Stahl RA: Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1997, 27:897–905.

    Google Scholar 

  40. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992, 140:95–107.

    PubMed  CAS  Google Scholar 

  41. Singh R, Alavi N, Singh AK, Leehey DJ: Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999, 48:2066–2073.

    Article  PubMed  CAS  Google Scholar 

  42. Ray PE, Bruggeman LA, Horikoshi S, et al.: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 1994, 45:177–184.

    PubMed  CAS  Google Scholar 

  43. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995–1001.

    PubMed  CAS  Google Scholar 

  44. Nakamura S, Nakamura I, Ma L, et al.: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251–259.

    Article  PubMed  CAS  Google Scholar 

  45. Wolf G, Killen PD, Neilson EG: Intracellular signalling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Regul 1991, 2:219–227.

    PubMed  CAS  Google Scholar 

  46. Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al.: Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens 2001, 10:321–329.

    Article  PubMed  CAS  Google Scholar 

  47. Wolf G, Ziyadeh FN, Thaiss F, et al.: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: role of the angiotensin type II receptor. J Clin Invest 1997, 100:1047–1058.

    PubMed  CAS  Google Scholar 

  48. Ruiz-Ortega M, Lorenzo O, Egido J: Angiotensin III increases monocytic chemotactic protein-1 and activates nuclear factor B in cultured mesangial cells and mononuclear cells. Kidney Int 2000, 57:2285–2298.

    Article  PubMed  CAS  Google Scholar 

  49. Marrero MB, Schieffer B, Paxton WG, et al.: Direct stimulation of JAK/STAT pathway by the angiotensin II AT1 receptor. Nature 1995, 375:247–250.

    Article  PubMed  CAS  Google Scholar 

  50. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through activation of transforming growth factor-synthesis in rat glomerular cells. J Clin Invest 1994, 93:2431–2437.

    Article  PubMed  CAS  Google Scholar 

  51. Border WA, Noble NA: Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998, 31:181–188.

    PubMed  CAS  Google Scholar 

  52. Wolf G, Ziyadeh FN, Stahl RA: Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med 1999, 77:556–564.

    Article  PubMed  CAS  Google Scholar 

  53. Moriyama T, Fujibayashi M, Fujiwara Y, et al.: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995, 6:95–101.

    PubMed  CAS  Google Scholar 

  54. Kato S, Luyckx VA, Ots M, et al.: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999, 56:1037–1048.

    Article  PubMed  CAS  Google Scholar 

  55. Ziyadeh FN, Hoffman BB, Han DC, et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015–8020. This is an important study because the authors show that blockade of TGF-â1 limits mesangial matrix expansion in a murine model of diabetes mellitus.

    Article  PubMed  CAS  Google Scholar 

  56. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growthrelated events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997, 52:1497–1510.

    Article  PubMed  CAS  Google Scholar 

  57. Ishidoya S, Morrissey J, McCracken R, et al.: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995, 47:1285–1294.

    Article  PubMed  CAS  Google Scholar 

  58. Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002, 39:486–492. This study reports the effect of combined ACE inhibition and Ang II blockade on the urinary excretion rate of TGF-â1, and the results suggest that the measurement of growth factors in the urine may be an important way to monitor treatment.

    Article  PubMed  CAS  Google Scholar 

  59. Sharma K, Ziyadeh FN, Alzahabi B, et al.: Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997, 46:854–859.

    Article  PubMed  CAS  Google Scholar 

  60. Sato H, Iwano M, Akai Y, et al.: Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol 1998, 18:490–494.

    Article  PubMed  CAS  Google Scholar 

  61. Parving H-H, Osterby R, Ritz E: Diabetic nephropathy. In The Kidney, edn 6. Edited by Brenner BM. Philadelphia: WB Saunders; 2000:1731–1773.

    Google Scholar 

  62. Mogensen C: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984, 310:356–360.

    Article  PubMed  CAS  Google Scholar 

  63. Mogensen CE, Keane WF, Bennett PH, et al.: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995, 346:1080–1084.

    Article  PubMed  CAS  Google Scholar 

  64. Nelson RG, Bennett PH, Beck GJ, et al.: Development and progression of renal disease in Pima Indians with noninsulin-dependent diabetes mellitus. N Engl J Med 1996, 335:1636–1642.

    Article  PubMed  CAS  Google Scholar 

  65. Shahinfar S, Dickson TZ, Ahmed T, et al.: Losartan in patients with type 2 diabetes mellitus and proteinuria: observations from the RENAAL Study. Kidney Int 2002, 62(Suppl 82):S64-S67.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Toronto, 13EN-243, Toronto General Hospital, 200 Elizabeth Street, M5G 2C4, Toronto, Ontario, Canada

    James W. Scholey MD, FRCP(C)

Authors
  1. James W. Scholey MD, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scholey, J.W. Angiotensin II and the glomerulus: Focus on diabetic kidney disease. Current Science Inc 5, 172–180 (2003). https://doi.org/10.1007/s11906-003-0075-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0075-0

Keywords

Search

Navigation